Lifevantage Corporation - Common Stock (LFVN)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 10, 2026Investment Snapshot
- Trading 9% below Graham Number — thin margin of safety
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 21.8% — good return on equity
- Revenue growing at 14% annually
Lifevantage Corporation - Common Stock (LFVN) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $67 million . Key value metrics: P/E ratio 9.3, P/B ratio 2.02, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Lifevantage Corporation - Common Stock — Fundamental Analysis Summary
Lifevantage Corporation - Common Stock (LFVN) is trading 9% below its Graham Number of $5.85, offering a thin margin of safety. The stock carries a low trailing P/E ratio of 9.3x.
On financial health, LFVN shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 21.8% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.85.
StockPik's composite Value Score for LFVN is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
LFVN reports a high gross margin of 78.5% (sector average: 40.1%) and a modest operating margin of 4.3%.
LFVN shows revenue growing at 14% year-over-year, with earnings growing at 234%.
LFVN pays a solid dividend yield of 3.4%.